What type of breast cancer is TRUQAP (capivasertib) for?
TRUQAP is used with Fulvestrant to treat breast cancer with the following indications:
- hormone receptor positive (HR+)
- human epidermal growth factor receptor 2 negative (HER2-)
- locally advanced or metastatic
- has an atypical PIK3CA, AKT1, or PTEN gene
- Breast cancer has worsened or returned within 12 months after completing treatment with at least one endocrine-based drug
Do I need to take a test to take TRUQAP?
TRUQAP works in patients who have an abnormal PIK3CA, AKT1, or PTEN gene. If you have not been tested for these biomarkers, you can be tested at anytime to determine your eligibility for TRUQAP. Consult with your doctor about biomarker testing.
How does TRUQAP work?
In people with HR+/HER2– metastatic breast cancer with an atypical PIK3CA, AKT1, and/or PTEN genes, overactive signaling in cancer cells can make the tumor grow. TRUQAP is an AKT inhibitor that works by disrupting signals from the AKT protein and other proteins along its pathway that can drive cancer growth.
How is TRUQAP administered?
TRUQAP is an oral tablet. The recommended dosage is 400 mg taken twice daily. The dosage is given for 4 days, then no doses for 3 days before beginning the cycle again for 4 days.
Why take TRUQAP vs Fulvestrant alone?
In a global clinical study, TRUQAP + fulvestrant has been shown to give people with HR+/HER2- metastatic breast cancer with atypical PIK3CA, AKT1, and/or PTEN genes more than twice as long without their cancer growing or spreading compared with the hormone therapy fulvestrant alone. This is called progression-free survival (PFS). TRUCAP + Fulvestrant keeps cancer from growing or spreading for ~2.5X longer than fulvestrant alone.
The PFS for TRUCAP + Fulvestrant was 7.3 months vs. 3.1 months with Fulvestrant alone. The global clinical trial included 708 people with HR+/HER2- metastatic breast cancer with or without abnormal PIK3CA, AKT1, and/or PTEN genes whose cancer grew or spread on hormone therapy.
